Cue Biopharma, Inc.

NasdaqCM:CUE Stock Report

Market Cap: US$64.0m

Cue Biopharma Management

Management criteria checks 2/4

Cue Biopharma's CEO is Dan Passeri, appointed in Aug 2016, has a tenure of 8.33 years. total yearly compensation is $3.02M, comprised of 20.1% salary and 79.9% bonuses, including company stock and options. directly owns 0.26% of the company’s shares, worth $166.22K. The average tenure of the management team and the board of directors is 5.2 years and 6.4 years respectively.

Key information

Dan Passeri

Chief executive officer

US$3.0m

Total compensation

CEO salary percentage20.1%
CEO tenure8.3yrs
CEO ownership0.3%
Management average tenure5.2yrs
Board average tenure6.4yrs

Recent management updates

Recent updates

Here's Why Cue Biopharma (NASDAQ:CUE) Can Manage Its Debt Despite Losing Money

Apr 16
Here's Why Cue Biopharma (NASDAQ:CUE) Can Manage Its Debt Despite Losing Money

Does Cue Biopharma (NASDAQ:CUE) Have A Healthy Balance Sheet?

Dec 30
Does Cue Biopharma (NASDAQ:CUE) Have A Healthy Balance Sheet?

Is Cue Biopharma (NASDAQ:CUE) Using Too Much Debt?

Aug 11
Is Cue Biopharma (NASDAQ:CUE) Using Too Much Debt?

Cue Biopharma shares rise ~10% on FDA fast track nod for head and neck cancer drug

Oct 04

Despite Lacking Profits Cue Biopharma (NASDAQ:CUE) Seems To Be On Top Of Its Debt

Sep 23
Despite Lacking Profits Cue Biopharma (NASDAQ:CUE) Seems To Be On Top Of Its Debt

News Flash: 4 Analysts Think Cue Biopharma, Inc. (NASDAQ:CUE) Earnings Are Under Threat

Aug 26
News Flash: 4 Analysts Think Cue Biopharma, Inc. (NASDAQ:CUE) Earnings Are Under Threat

Analysts Just Shipped A Huge Upgrade To Their Cue Biopharma, Inc. (NASDAQ:CUE) Estimates

Aug 10
Analysts Just Shipped A Huge Upgrade To Their Cue Biopharma, Inc. (NASDAQ:CUE) Estimates

Analysts Have Just Cut Their Cue Biopharma, Inc. (NASDAQ:CUE) Revenue Estimates By 23%

May 18
Analysts Have Just Cut Their Cue Biopharma, Inc. (NASDAQ:CUE) Revenue Estimates By 23%

Cue Biopharma (NASDAQ:CUE) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

May 12
Cue Biopharma (NASDAQ:CUE) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Cue Biopharma: A First Assessment

May 11

Earnings Beat: Cue Biopharma, Inc. (NASDAQ:CUE) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Mar 19
Earnings Beat: Cue Biopharma, Inc. (NASDAQ:CUE) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Cue Biopharma: Too Long To Arrive At Topline Trial Data

Feb 23

We Think Cue Biopharma (NASDAQ:CUE) Can Afford To Drive Business Growth

Nov 04
We Think Cue Biopharma (NASDAQ:CUE) Can Afford To Drive Business Growth

CEO Compensation Analysis

How has Dan Passeri's remuneration changed compared to Cue Biopharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$45m

Jun 30 2024n/an/a

-US$47m

Mar 31 2024n/an/a

-US$50m

Dec 31 2023US$3mUS$605k

-US$51m

Sep 30 2023n/an/a

-US$52m

Jun 30 2023n/an/a

-US$52m

Mar 31 2023n/an/a

-US$52m

Dec 31 2022US$1mUS$748k

-US$53m

Sep 30 2022n/an/a

-US$47m

Jun 30 2022n/an/a

-US$49m

Mar 31 2022n/an/a

-US$46m

Dec 31 2021US$2mUS$531k

-US$44m

Sep 30 2021n/an/a

-US$47m

Jun 30 2021n/an/a

-US$44m

Mar 31 2021n/an/a

-US$44m

Dec 31 2020US$6mUS$501k

-US$45m

Sep 30 2020n/an/a

-US$43m

Jun 30 2020n/an/a

-US$40m

Mar 31 2020n/an/a

-US$38m

Dec 31 2019US$1mUS$395k

-US$37m

Sep 30 2019n/an/a

-US$39m

Jun 30 2019n/an/a

-US$45m

Mar 31 2019n/an/a

-US$43m

Dec 31 2018US$834kUS$345k

-US$39m

Sep 30 2018n/an/a

-US$38m

Jun 30 2018n/an/a

-US$30m

Mar 31 2018n/an/a

-US$27m

Dec 31 2017US$410kUS$325k

-US$23m

Compensation vs Market: Dan's total compensation ($USD3.02M) is above average for companies of similar size in the US market ($USD653.16K).

Compensation vs Earnings: Dan's compensation has increased whilst the company is unprofitable.

CEO

Dan Passeri (63 yo)

8.3yrs

Tenure

US$3,015,480

Compensation

Mr. Daniel R. Passeri, also known as Dan, MSc. J.D. has been the Chief Executive Officer and Director of Cue Biopharma, Inc. since August 2016 and also served as its President since August 2016 until Octob...

Leadership Team

NamePositionTenureCompensationOwnership
Daniel Passeri
CEO & Director8.3yrsUS$3.02m0.26%
$ 166.2k
Kerri-Ann Millar
Chief Financial Officer6.6yrsUS$1.16m0.023%
$ 14.5k
Ronald Seidel
Co-Founderno dataUS$316.63kno data
Rodolfo Chaparro
Co-Founder & Senior Advisorno dataUS$316.63kno data
Steven Almo
Co-Founder and Chairman of Scientific & Clinical Advisory Boardno datano datano data
Colin Sandercock
Senior VP7yrsUS$625.51kno data
Matteo Levisetti
Chief Medical Officer3.8yrsno datano data
Lucinda Warren
Chief Business Officerless than a yearno datano data
Daniel Baker
Interim Chief Development Officerless than a yearno datano data

5.2yrs

Average Tenure

59yo

Average Age

Experienced Management: CUE's management team is seasoned and experienced (5.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Daniel Passeri
CEO & Director8.3yrsUS$3.02m0.26%
$ 166.2k
Steven Almo
Co-Founder and Chairman of Scientific & Clinical Advisory Board9.9yrsno datano data
Frederick Driscoll
Independent Director6.5yrsUS$76.31k0%
$ 0
Frank Morich
Independent Chairman of the Board6.4yrsUS$106.27k0.044%
$ 28.3k
Peter Kiener
Independent Director8.8yrsUS$144.18k0.00056%
$ 358.3
Hidde L. Ploegh
Member of Scientific & Clinical Advisory Boardno datano datano data
Rafi Ahmed
Member of Scientific Advisory Board1.8yrsno datano data
Kenneth Pienta
Clinical Advisor1.9yrsno datano data
Abul K. Abbas
Member of Scientific Advisory Board3.8yrsno datano data
Karolina Palucka
Member of Scientific & Clinical Advisory Board7.8yrsno datano data
Anish Suri
Member of Scientific & Clinical Advisory Boardless than a yearUS$1.21m0.21%
$ 137.0k
Michael Kalos
Member of Scientific Advisory Board3.8yrsno datano data

6.4yrs

Average Tenure

64yo

Average Age

Experienced Board: CUE's board of directors are considered experienced (6.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 12:06
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cue Biopharma, Inc. is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Madhu KumarBaird
Brian SkorneyBaird
Zhiqiang ShuBerenberg